Biopharmaceutical company CoTherix Inc. said Wednesday its third-quarter profit narrowed as sales more than doubled on its drug Vantavis, beating Wall Street expectations.

The company lost $2.8 million, or 10 cents per share, compared with $6.2 million, or 26 cents per share, a year ago. Revenue jumped 118 percent to $18.4 million from $8.4 million.

Analysts polled by Thomson Financial expected a loss of 32 cents per share on revenue of $18.2 million.

The company's inhaled pulmonary arterial hypertension treatment Vantavis, launched in March, brought in all the revenue for quarter.

The company said it expects sales of Vantavis to bring in between $100 million and $105 million in sales during 2007. Analysts expect the company to report $107 million in sales for the year.

Shares of CoTherix gained 83 cents, or 11.3 percent, to $8.16 in aftermarket electronic trading, from their close at $7.33 on the Nasdaq Wednesday.